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Impact of CYP2C19 polymorphisms on 
antiplatelet efficacy of clopidogrel in 
patients after myocardial infarction
AbstrACt
Aim. The aim of this study was to evaluate the complex effects of polymorphisms of the gene encoding 
the CYP2C19 enzyme on the antiplatelet efficacy of clopidogrel during follow-up visits. 
Material and methods. This study was designed as a prospective, single-centre observational clinical trial 
with a one-year follow-up. Data from 178 patients on clopidogrel, taken during follow-up visits, was analysed. 
Results. Patients were divided into three groups according to the expected metabolic activity of the 
CYP2 C19 enzyme: ‘superior metabolisers’ (681 GG + 806 CT or TT), ‘neutral metabolisers’ 
(681 GG + 806 CC and 681 GA or AA + 806 CT or TT) and ‘inferior metabolisers’ (681 GA or AA + 806 CC). 
The antiplatelet effect of clopidogrel was strongest in ‘superior metabolisers’ and weakest in ‘inferior metab-
olisers’, as assessed by adenosine diphosphate (ADP)-induced platelet aggregation and the VASP assay. 
Comparison of results of ADP-induced platelet aggregation measurements in pairs showed a significant 
difference (p = 0.03) only between ‘superior metabolisers’ vs. ‘inferior metabolisers’. With the VASP assay, 
significant differences between ‘superior metabolisers’ and ‘neutral metabolisers’ (p = 0.013), ‘neutral 
metabolisers’ and ‘inferior metabolisers’ (p = 0.015), and ‘superior metabolisers’ and ‘inferior metabolisers’ 
(p = 0.00003) were found. No impact on clinical outcome was present. A tendency for an increasing 
need for a clopidogrel-to-prasugrel switch was observed with a decrease in CYP2C19 metabolic activity. 
Conclusion. Multiple polymorphisms of the gene encoding the CYP2C19 enzyme have a significant im-
pact on the antiplatelet efficacy of clopidogrel during follow-up visits; however, their influence on clinical 
outcome needs further clarification. 
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Introduction
According to current guidelines, myocardial infarc-
tion survivors require implementation of secondary 
cardiovascular prevention based on a long-term ther-
apeutic schedule. One of the key elements of such 
a schedule, besides the modification of risk factors, is 
pharmacotherapy including antiplatelet agents: aspirin 
and P2Y12 receptor inhibitor. Despite the availability 
of new agents such as prasugrel or ticagrelor, clopi-
dogrel remains the most widely used P2Y12 receptor 
inhibitor. Clopidogrel is a prodrug which requires 
a two-step oxidation in the liver involving cytochrome 
P450 enzymes to transform into active metabolite [1, 2]. 
Substantial variability of antiplatelet action is an im-
portant limitation of clopidogrel [3]. It has been shown 
that as many as 5–10% of patients do not respond to 
clopidogrel (‘non-responders’), and approximately 
25% are characterised by an incomplete response to 
the drug [4]. After excluding external causes of poor 
response to clopidogrel due to low patient adherence to 
medication or potential drug-drug interactions, genetic 
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factors should be taken into account [4, 5]. Genes en-
coding the cytochrome P450 enzymes are polymorphic 
and have a significant influence on the metabolism of 
clopidogrel [6, 7]. There are 25 known gene variants 
encoding the CYP2C19 enzyme [8]. Some of the alleles 
have a strong effect on the function of the enzyme 
[9–11]. The presence of two wild alleles (homozygote 
CYP2C19 *1/*1) implies normal CYP2C19 function. 
Mutations of CYP2C19 *2 and CYP2C19 *3 are the com-
monest variants causing loss of activity of the enzyme. 
Alleles CYP2C19 — *4 and *5 also cause inactivation 
of the enzyme, but they are very rare [12–16]. On the 
other hand, the CYP2C19 *17 mutation enhances the 
activity of the enzyme [17, 18]. Due to their prevalence 
and modifying influence on the enzymatic activity, two 
alleles: CYP2C19 –681 G>A and CYP2C19 –806C>T 
and –3402C>T, labelled as CYP2C19 *2 and CY-
P2C19 *17 respectively, have the greatest impact on 
the metabolism of clopidogrel. Almost all available 
knowledge regarding the impact of CYP2C19 meta-
bolic activity on the antiplatelet effect of clopidogrel is 
based on acute-phase studies. Little is known about 
the complex effect of different polymorphisms on 
platelet aggregation in on-clopidogrel patients. More-
over, according to the contradictory results of several 
studies, an association between genetic variants of 
CYP2C19 and clinical outcome is dubious. 
The aim of this study was to evaluate the complex 
effects of polymorphisms of the gene encoding the CY-
P2C19 enzyme on the antiplatelet efficacy of clopidogrel 
during follow-up visits.
Materials and methods
Study design and patient characteristics
This study was designed as a prospective, sin-
gle-centre observational clinical trial with a one-year 
follow-up. The studied population comprised 191 con-
secutive patients treated with primary percutaneous cor-
onary intervention for acute myocardial infarction, who 
gave informed written consent. Exclusion criteria were 
defined as follows: the need for prolonged use of hepa-
rin or fondaparinux, oral anticoagulant therapy, bleeding 
disorders (including thrombocytopenia < 100 × 103/μL), 
anaemia (hemoglobin < 10.0 g/dL), active inflamma-
tion, heart failure in New York Heart Association class 
III and IV and life expectancy < 1 year. In-hospital man-
agement and discharge treatment recommendations 
strictly adhered to the European Society of Cardiology 
guidelines. Maintenance antiplatelet therapy consisted 
of clopidogrel 75 mg and aspirin 100 mg once a day. 
Follow-up visits were scheduled at three, six and nine 
months after discharge. During every visit, adenosine di-
phosphate (ADP)-induced platelet aggregation, platelet 
reactivity index (PRI) with the VASP assay and bleeding 
time were assessed. In cases of ADP-induced platelet 
aggregation > 41 U (borderline value of the highest 
tertile according to our previous studies) in patients 
who declared systematic intake of clopidogrel, the drug 
was switched to prasugrel.
The primary study end-point was defined as the 
necessity of a clopidogrel-to-prasugrel switch guided by 
ADP-induced platelet aggregation measurements. The 
secondary study end-point was a combined clinical end-
point consisting of death, acute coronary syndrome and 
unscheduled cardiovascular hospitalization.
The study protocol was approved by the Ethical 
Committee of Nicolaus Copernicus University. 
Platelet function assessment
ADP-induced platelet aggregation examination was 
performed using impedance aggregometry. Whole 
blood was tested with a Multiplate Analyser (Medical 
Cyclotron, Munich, Germany). Platelet aggregation rate, 
assessed as the area under the curve of the aggregation 
curve (AUC), was expressed in units of aggregation (U).
For the determination of vasodilator stimulated 
phosphoprotein phosphorylation in whole blood 
samples, a standardised reagent — Purified Mouse 
Anti-VASP (Becton, Dickinson & Co., Franklin Lakes, 
NJ, USA) and flow cytometer (Becton, Dickinson & 
Co., Franklin Lakes, NJ, USA) were used. Platelet 
reactivity with the VASP assay was expressed as PRI 
and determined based on the fluorescence of blood 
samples after the addition of the monoclonal antibody.
PRI was defined as the mean fluorescence intensity 
(MFI) after incubation with PGE1 and ADP according to 
the following formula: PRI = [(MFI(PGE1) – MFI(PGE1+ADP)/ 
/MFI(PGE1)] × 100. The ratio is expressed as mean 
percentage platelet reactivity, inversely correlated with 
clopidogrel treatment efficiency.
CYP2C19 gene polymorphism assessment
Deoxyribonucleic acid was extracted from blood 
samples according to a standard organic procedure. 
CYP2C19*17 (CYP2C19_-806_C>T, rs12248560) 
was genotyped with a commercially available vali-
dated drug metabolism genotyping assay (TaqMan 
Drug Metabolism Genotyping Assay C_469857_10, 
Applied Biosystems, Foster City, CA, USA) with the ABI 
Prism Sequence Detector 7000 (Applied Biosystems) 
in accordance with the manufacturer’s instructions. 
CYP2C19*2 (CYP2C19_681_G>A; rs4244285) was 
genotyped with real-time allelic discrimination assay 
on an ABI Prism Sequence Detector 7000 (Applied 
Biosystems) as described previously [2]. 
The proper assessment of genotypes was evalu-
ated in a random sequencing of PCR products using 
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a BigDye Terminator v. 3.1 sequencing kit and a 3130xl 
Genetic Analyser (Applied Biosystems). The compatibil-
ity between the results of real-time allelic discrimination 
and direct sequencing was confirmed. Genetic analysis 
was performed at the Department of Molecular and 
Forensic Genetics, CM UMK. 
Statistical analysis 
According to the Shapiro-Wilk test, the investigat-
ed continuous variables were non-normally distrib-
uted; therefore, they were reported as medians and 
interquartile ranges. For comparisons between two 
and three groups, the Mann-Whitney unpaired rank 
sum test and the Kruskal–Wallis one-way analysis 
of variance were used, respectively. Categorical 
variables were expressed as the number of patients 
presenting the given feature and the percentage of 
patients in the analysed group. Categorical variables 
were compared using the c2 test with the Yates’ cor-
rection if required. The Cochran–Armitage test was 
used to assess the presence of linear trend among 
categorical variables. Differences were considered 
significant at p < 0.05. The statistical analysis was 
carried out using the Statistica 10.0 package (Stat-
Soft, Tulsa, OK, USA). 
Results
A total of 191 patients were included into the study 
(Tab. 1). Thirteen of them withdrew from the study be-
fore the first follow-up visit. Data from 178 patients on 
clopidogrel, taken during follow-up visits (435 visits), 
was analysed. 
Effects of single CYP2C19 polymorphisms 
Due to the small number of patients being homo-
zygous for CYP2C19*2 681 G > A, all carriers of the 
mutant alelle combined in one group consisting of ho-
mozygotes AA (n = 2) and heterozygotes GA (n = 33) 
were compared to GG homozygotes (n = 143). An 
analogous division was applied regarding the presence 
of the CYP2C19*17 -806 C> T mutant allele. TT homo-
zygotes (n = 13) were combined with heterozygous CT 
patients (n = 72) and compared to CC homozygotes 
(n = 93). The analysis of ADP-induced platelet aggre-
gation and PRI from follow-up visits in patients on the 
standard maintenance dose of clopidogrel showed an 
inhibitory effect of CYP2C19*2 (Tab. 2) and an esca-
lating impact of CYP2C19*17 allele on the antiplatelet 
effect of clopidogrel (Tab. 3). No significant impact of 
both polymorphisms on the primary and secondary 
end-points was observed.
Complex effect of CYP2C19 polymorphisms 
To allow for a comprehensive assessment of the 
impact of both these polymorphisms on the individual 
variation of clopidogrel antiplatelet action, patients 
were divided into three groups according to the ex-
pected metabolic activity of the CYP2C19 enzyme: 
‘superior metabolisers’ (681 GG + 806 CT or TT), 
‘neutral metabolisers’ (681 GG + 806 CC and 681 GA 
Table 1. Characteristics of the studied population
Feature
Median (upper quartile  
— lower quartile) number (%) 
(n = 191)
Male
Age [years]
Height [cm]
Body mass [kg]
Waist circumference [cm]
Body mass index > 25 kg/m2
Hypertension
Diabetes
Smokers
LDL cholesterol ≥ 115 mg/dL
142 (74.3%)
60.0 (53.0–67.0)
169.9 (164.0–176.0)
80.0 (70.0–90.0)
96.0 (89.0–103.5)
141 (73.8%)
106 (55.5%)
67 (35.1%)
99 (51.8%)
143 (74.9%)
Table 2. Results of ADP-induced platelet aggregation, PRI and bleeding time during follow-up visits with regard to the 
presence of CYP2C19*2 -681 G>A allele
CYP2C19*2 681 G>A
GG
n = 143
GA or AA
n = 35 p
ADP-induced platelet aggregation [U] 17.0 (10.0–27.0) 21.0 (16.0–33.0) 0.0005
PRI [%] 49.7 (34.2–63.0) 63.2 (46.2–74.9) 0.00003
Bleeding time [min] 4.0 (2.5–6.0) 3.5 (2.0–6.0) ns
Primary study end-point 19 (13.3%) 7 (20.0%) ns
Death
ACS
CV hospitalization
Secondary study end-point
1 (0.7%)
8 (5.6%)
23 (16.1%)
26 (18.2%)
0 (0.0%)
2 (5.7%)
7 (20.0%)
7 (20.0%) ns
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or AA + 806 CT or TT), and ‘inferior metabolisers’ 
(681 GA or AA + 806 CC). The antiplatelet effect of 
clopidogrel was strongest in ‘superior metabolisers’ 
and weakest in ‘inferior metabolisers’, as assessed 
by ADP-induced platelet aggregation by PRI, but not 
by bleeding time (Tab. 4). Comparing the results of 
ADP-induced platelet aggregation measurements in 
pairs showed a significant difference (p = 0.03) only 
between extreme groups, i.e. ‘superior metabolisers’ 
vs. ‘inferior metabolisers’. With PRI assessment, sig-
nificant differences between ‘superior metabolisers’ 
and ‘neutral metabolisers’ (p = 0.013), ‘neutral me-
tabolisers’ and ‘inferior metabolisers’ (p = 0.015), 
and ‘superior metabolisers’ and ‘inferior metabolisers’ 
(p = 0.00003) were found. Bleeding time did not differ 
between the groups.
During the observation period, the primary end-point 
occurred in 26 (14.6%), and the secondary end-point 
in 33 (18.5%) of the 178 patients. 
Despite significant differences of on-clopidogrel 
platelet activity as assessed by ADP-induced platelet 
aggregation and PRI, no impact on clinical outcome 
was present. A tendency towards an increasing need 
for a clopidogrel-to-prasugrel switch was observed 
with a decrease in CYP2C19 metabolic activity (Fig. 1). 
Discussion
CYP2C19 and clopidogrel pharmacodynamics
Combinations of different CYP2C19 alleles cause var-
ied effects on the activity of this enzyme and, consequently, 
on the metabolism of clopidogrel [19]. The prevalence of 
alleles is ethnically variable. A study published by Sibbing 
Table 3. Results of ADP-induced platelet aggregation, PRI and bleeding time during follow-up visits with regard to the 
presence of CYP2C19*17 -806 C>T allele 
CYP2C19*17 -806 C>T
CC
n = 93
CT or TT
n = 85 p
ADP-induced platelet aggregation [U] 19.0 (11.0–29.0) 17.0 (10.0–27.0) ns
PRI [%] 54.7 (42.0–67.3) 48.6 (30.5–64.6) 0.006
Bleeding time [min] 4.0 (2.5–6.0) 3.5 (2.5–6.0) ns
Primary study end-point 14 (15.1%) 12 (14.1%) ns
Death
ACS
CV hospitalization
Secondary study end-point
1 (1.1%)
6 (6.5%)
14 (15.1%)
16 (17.2%)
0 (0.0%)
4 (4.7%)
16 (18.8%)
17 (20.0%) ns
Table 4. Results of ADP-induced platelet aggregation, PRI, bleeding time during follow-up visits and prevalence of 
study end-points with regard to the expected metabolic activity of CYP2C19 enzyme
‘Superior metabolisers’
n = 71
‘Neutral metabolisers’
n = 86
‘Inferior metabolisers’
n = 21 p
ADP-induced platelet [U] 
aggregation
16.5 (9.0–26.0) 18.0 (11.0–29.0) 22.5 (15.5–32.5) 0.03
PRI [%] 47.9 (29.5–61.0) 53,7 (39.9–66.6) 63.3 (47.6–72.0) < 0.0001
Bleeding time [min] 3.5 (2.5–5.5) 4.0 (3.0–6.0) 3.3 (2.0–5.5) ns
Primary study end-point 9 (12.7%) 13 (15.1%) 4 (19.0%) ns
Death
ACS
CV hospitalization
Secondary study end-point
0 (0.0%)
3 (4.2%)
12 (16.9%)
13 (18.3%)
1 (1.2%)
6 (7.0%)
15 (17.4%)
17 (19.8%)
0 (0.0%)
1 (4.8%)
3 (14.3%)
3 (14.3%) ns
Figure 1. Proportion of patients requiring clopidogrel-to-
prasugrel switch according to CYP2C19 metabolic status
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et al. [20] showed that in a German population, 73% were 
CYP2C19*1/*1 homozygotes, 25% were heterozygotes 
with CYP2C19*2 as one of two alleles, and only 2% were 
CYP2C19*2/*2 homozygotes. Similar prevalences have 
been found in French and Polish populations [9, 21]. Due 
to the relatively rare occurrence of CYP2C19*2/*2 gen-
otype, the analysis in clinical trials is usually based on 
a comparison of homozygotes CYP2C19*1/*1 with car-
riers of at least one CYP2C19*2 loss-of-function mutant 
allele (CYP2C19*1/*2 or CYP2C19*2/*2). Carriers of 
CYP2C19*2 are more common in populations of non-Eu-
ropean ancestry; they account for about 40% of patients of 
African ancestry and over 55% of East Asian populations 
[5, 22]. The CYP2C19*17 allele is relatively common, 
being observed in 43% of Poles, 41% of Germans, 20% 
of French, 18% of Swedes and Ethiopians, and only 4% 
of the Chinese [17, 18, 21].
Hulot et al. [13] found a significant reduction of 
ADP-induced platelet aggregation in CYP2C19*1/*1 ho-
mozygotes, while in carriers of CYP2C19*2 allele the 
response to clopidogrel was much weaker in healthy 
subjects. Mega et al. [5] revealed significantly lower 
concentrations of clopidogrel active metabolite in CYP2- 
C19*2 carriers compared to non-carriers. This was in line 
with pharmacodynamic findings: the maximum induced 
platelet aggregation was about 25% lower among car-
riers of the loss-of-function allele. These observations 
were confirmed in a group of 797 consecutive patients 
who underwent coronary angioplasty [8]. Carriers of 
the CYP2C19*2 allele were characterised by higher 
residual platelet aggregation, both after the loading 
dose (600 mg) and on the maintenance dose (75 mg) 
of clopidogrel. This phenomenon was also confirmed in 
our study by PRI and ADP-induced platelet aggregation 
measurements performed during follow-up.
Frere et al. [10] studied the effect of CYP2C19*17 al-
lele on the metabolism of clopidogrel in patients with 
acute coronary syndrome. The loading dose of clopido-
grel (600 mg) was associated with a significantly greater 
reduction in PRI in carriers of CYP2C19*17 compared 
to non-carriers. In another study, clopidogrel-treated 
patients undergoing percutaneous coronary interven-
tion, both heterozygous CYP2C19*1/*17 and those 
who were CYP2C19*17/*17 homozygotes, were char-
acterised by significantly lower ADP-induced platelet 
aggregation than CYP2C19*1/*1 homozygotes [23]. 
In this study, we proved enhancement of clopidogrel 
metabolism according to follow-up PRI measurements. 
Comprehensive assessment of both CYP2C19*2 and 
CYP2C19*17 genetic variants may better reflect the in-
dividual variation of clopidogrel’s antiplatelet action. We 
defined three groups according to the expected meta-
bolic activity of the CYP2C19 enzyme. As expected, the 
attenuation of platelet aggregation was highest in ‘supe-
rior metabolisers’ and lowest in ‘inferior metabolisers’, as 
assessed by ADP-induced platelet aggregation by PRI. 
CYP2C19 and clinical outcome
Pharmacodynamic and pharmacokinetic findings 
were consistent with the results of some recently 
published clinical studies [14, 24]. Collet et al. [9] 
found an increased incidence of coronary events in 
CP2C19*2 allele carriers compared to CYP2C19*1/*1 homo- 
zygotes. In addition, the carriage of the loss-of-function 
allele was an independent risk factor for the composite 
end-point of death, myocardial infarction, and urgent 
revascularisation [9]. In a study published by Sibbing et 
al. [20], the carriage of CYP2C19*2 allele was associated 
with a higher risk of myocardial infarction and ischaemic 
stroke (p = 0.001) in patients treated with clopidogrel 
due to stent implantation. The presence of this allele 
was an independent risk factor of stent thrombosis [20]. 
In the genetic substudy of the TRITON-TIMI 38 trial, the 
risks of the composite end-point (death from cardiovas-
cular causes, myocardial infarction, stroke), and of stent 
thrombosis, were significantly higher among carriers of 
CYP2C19*2 allele compared to non-carriers [5]. In a re- 
gistry published by Tang et al. [22], the risk of ischaemic 
events increased with the incidence of CYP2C19 loss-
of-function alleles in 670 patients after percutaneous 
coronary intervention. On the other hand, Tello-Mon-
toliu et al. [25] revealed that the VASP phosphoryla-
tion measurement detected significant differences in 
on-clopidogrel platelet reactivity between the wild-type 
subjects and the CYP2C19*2 or *17 allele carriers, 
although no significant difference in the occurrence of 
adverse events at six-month follow-up was found. Sim-
ilarly, the carriage of CYP2C19 loss-of-function alleles 
as well as gain-of-function alleles did not influence the 
rate of ischaemic events in a population of 4,819 sta-
ble patients with stable coronary artery disease in the 
CHARISMA genetics study [26]. A meta-analysis pub-
lished by Zabalza et al. [24] also showed that patients 
who carried a loss-of-function allele did not present with 
an increased risk of a cardiovascular event, except for 
stent thrombosis. However, the gain-of-function allele 
was associated with a lower risk of cardiovascular events 
and a higher risk of major bleeding [24]. Similarly, data 
from six clinical studies has demonstrated that carriers 
of the CYP2C19*17 variant had a marked protection 
against recurrent cardiovascular events in patients 
with coronary artery disease compared to non-carriers 
[27]. Both in separate analyses and in comprehensive 
evaluation of CYP2C19*2 and CYP2C19*17 carriage, 
we have not found significant impacts on the primary 
nor the secondary end-point, although the proportion of 
patients requiring a clopidogrel-to-prasugrel switch well 
reflected the results of ADP-induced platelet aggregation 
measurements and PRI. The prevalence of the combined 
clinical end-point did not follow the results of platelet 
function assessment. Inconsistency between platelet ag-
gregation and the incidence of the secondary end-point 
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can be at least partially related to a higher proportion of 
drug switch for the stronger P2Y12 inhibitor in patients 
with a weak effect of clopidogrel.
Limitations of the study
The main limitation of this study was uncertainty 
regarding patients’ adherence to medication during 
follow-up. Blood samples for the evaluation of platelet 
function were taken only from patients declaring sys-
tematic intake of clopidogrel; however, this was not 
objectively proved. 
Conclusions
Multiple polymorphisms of the gene encoding the CY-
P2C19 enzyme have a significant impact on the antiplate-
let efficacy of clopidogrel during follow-up visits, but their 
influence on clinical outcome needs further clarification. 
Acknowledgements
The present contribution is a project of Systematic 
Investigation and Research on Interventions and Out-
comes (SIRIO)-MEDICINE, a group of senior scientists 
and fellows collaborating worldwide to pursue research 
and innovation in medicine.
references
1. Pereillo JM, Maftouh M, Andrieu A et al. Structure and stereochemistry 
of the active metabolite of clopidogrel. Drug Metab Dispos 2002; 30: 
1288–1295.
2. Siller-Matula JM, Delle-Karth G, Lang IM et al. Phenotyping vs. geno-
typing for prediction of clopidogrel efficacy and safety: the PEGASUS-
-PCI study. J Thromb Haemost 2012;10:529–542. 
3. Kozinski M, Bielis L, Wisniewska-Szmyt J et al. Diurnal variation in 
platelet inhibition by clopidogrel. Platelets 2011; 22:579–587. 
4. Kubica A, Koziński M, Grześk G, Goch A. Clinical significance of 
interactions between clopidogrel and proton pump inhibitors. Kardiol 
Pol 2011; 69: 610–616. 
5. Mega JL, Close SL, Wiviott SD et al. Cytochrome p-450 polymorphi-
sms and response to clopidogrel. N Engl J Med 2009; 360: 354–362.
6. Navarese EP, Verdoia M, Schaffer A et al. Ischaemic and bleeding 
complications with new, compared to standard, ADP-antagonist regi-
mens in acute coronary syndromes: a meta–analysis of randomized 
trials. QJM. 2011; 104: 561–569. 
7. Simon T, Verstuyft C, Mary-Krause M et al. French Registry of Acute 
ST–Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) 
Investigators: Genetic determinants of response to clopidogrel and 
cardiovascular events. N Engl J Med 2009; 360: 363–375.
8. Trenk D, Hochholzer W, Fromm MF et al. Cytochrome P450 2C19 
681G_A polymorphism and high on–clopidogrel platelet reactivity 
associated with adverse 1-year clinical outcome of elective percuta-
neous coronary intervention with drug-eluting or bare-metal stents. 
J Am Coll Cardiol 2008; 51: 1925–1934.
9. Collet JP, Hulot JS, Pena A et al. Cytochrome P450 2C19 polymorphism 
in young patients treated with clopidogrel after myocardial infarction: 
a cohort study. Lancet 2009; 373: 309–317.
10. Frére C, Cuisset T, Gaborit B, Alessi MC, Hulot JS. The CYP2C19*17 
allele is associated with better platelet response to clopidogrel in 
patients admitted for non-ST acute coronary syndrome. J Thromb 
Haemost 2009; 7: 1409–1411.
11. Sim SC, Risinger C, Dahl ML et al. A common novel CYP2C19 gene 
variant causes ultrarapid drug metabolism relevant for the drug re-
sponse to proton pump inhibitors and antidepressants. Clin Pharmacol 
Ther 2006; 79: 103–113.
12. Gurbel PA, Bliden KP, Antonino MJ et al. The effect of elinogrel on high 
platelet reactivity during dual antiplatelet therapy and the relation to 
CYP2C19*2 genotype: first experience in patients. J Thromb Haemost 
2010; 8: 43–53.
13. Hulot JS, Bura A, Villard E et al. Cytochrome P450 2C19 loss-of-function 
polymorphism is a major determinant of clopidogrel responsiveness 
in healthy subjects. Blood 2006; 108: 2244–2247.
14. Hulot JS, Collet JP, Silvain J et al. Cardiovascular risk in clopidogrel–tre-
ated patients according to cytochrome P450 2C19*2 loss-of-function 
allele or proton pump inhibitor co-administration. A systematic meta-
-analysis. J Am Coll Cardiol 2010; 56: 134–143.
15. Storey RF. Clopidogrel in acute coronary syndrome: to genotype or 
not? Lancet 2009; 373: 276–278.
16. Wallentin L, Becker RC, Budaj A et al. Ticagrelor versus clopidogrel 
in patients with acute coronary syndromes. N Engl J Med 2009; 361: 
1045–1057.
17. James S, Akerblom A, Cannon CP et al. Comparison of ticagrelor, 
the first reversible oral P2Y(12) receptor antagonist, with clopidogrel 
in patients with acute coronary syndromes: rationale, design, and 
baseline characteristics of the PLATelet inhibition and patient Outcomes 
(PLATO) trial. Am Heart J 2009; 157: 599–605.
18. Varenhorst C, James S, Erlinge D et al. Genetic variation of CYP2C19 
affects both pharmacokinetic and pharmacodynamic responses to 
clopidogrel but not prasugrel in aspirin-treated patients with coronary 
artery disease. Eur Heart J 2009; 30: 1744–1752.
19. Maeda A, Ando H, Asai T et al. Differential impacts of CYP2C19 gene 
polymorphisms on the antiplatelet effects of clopidogrel and ticlopidine. 
Clin Pharmacol Ther 2011; 89: 229–233.
20. Sibbing D, Stegherr J, Latz W et al. Cytochrome P450 2C19 loss-of-
-function polymorphism and stent thrombosis following percutaneous 
coronary intervention. Eur Heart J 2009; 30: 916–922. 
21. Kubica A, Kozinski M, Grzesk G, Fabiszak T, Navarese EP, Goch A. 
Genetic determinants of platelet response to clopidogrel. J Thromb 
Thrombolysis 2011; 32: 459–466.
22. Tang XF, Wang J, Zhang JH et al. Effect of the CYP2C19*2 and *3 
genotypes, ABCB1 C3435T and PON1 Q192R alleles on the phar-
macodynamics and adverse clinical events of clopidogrel in Chinese 
people after percutaneous coronary intervention. Eur J Clin Pharmacol 
2012 [Epub ahead of print].
23. Sibbing D, Gebhard D, Koch W et al. Cytochrome 2C19*17 allelic 
variant, platelet aggregation, bleeding events, and stent thrombosis in 
clopidogrel-treated patients with coronary stent placement. Circulation 
2010; 121: 512–518.
24. Zabalza M, Subirana I, Sala J et al. Meta-analyses of the association 
between cytochrome CYP2C19 loss- and gain-of-function polymor-
phisms and cardiovascular outcomes in patients with coronary artery 
disease treated with clopidogrel. Heart 2012; 98: 100–108.
25. Tello-Montoliu A, Jover E, Marín F et al. Influence of CYP2C19 po-
lymorphisms in platelet reactivity and prognosis in an unselected 
population of non ST elevation acute coronary syndrome. Rev Esp 
Cardiol 2012; 65: 219–226. 
26. Bhatt DL, Paré G, Eikelboom JW. CHARISMA Investigators: The 
relationship between CYP2C19 polymorphisms and ischaemic and 
bleeding outcomes in stable outpatients: the CHARISMA genetics 
study. Eur Heart J 2012; 33: 2143–2150. 
27. Li Y, Tang HL, Hu YF, Xie HG. The gain-of-function variant allele 
CYP2C19*17: a double-edged sword between thrombosis and 
bleeding in clopidogrel-treated patients. J Thromb Haemost 2012; 
10: 199–206. 
